Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Onconetix (ONCO) EBITDA (2023 - 2025)

Historic EBITDA for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to -$8.9 million.

  • Onconetix's EBITDA fell 195219.91% to -$8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.7 million, marking a year-over-year decrease of 21.55%. This contributed to the annual value of -$63.8 million for FY2024, which is 8212.27% down from last year.
  • As of Q3 2025, Onconetix's EBITDA stood at -$8.9 million, which was down 195219.91% from -$144660.0 recorded in Q2 2025.
  • Onconetix's EBITDA's 5-year high stood at -$144660.0 during Q2 2025, with a 5-year trough of -$33.2 million in Q4 2024.
  • Over the past 3 years, Onconetix's median EBITDA value was -$8.4 million (recorded in 2025), while the average stood at -$10.6 million.
  • Over the last 5 years, Onconetix's EBITDA had its largest YoY gain of 9898.34% in 2025, and its largest YoY loss of 195219.91% in 2025.
  • Onconetix's EBITDA (Quarter) stood at -$20.0 million in 2023, then plummeted by 66.12% to -$33.2 million in 2024, then soared by 73.03% to -$8.9 million in 2025.
  • Its EBITDA stands at -$8.9 million for Q3 2025, versus -$144660.0 for Q2 2025 and -$8.4 million for Q1 2025.